Navigation Links
T1D Exchange Awarded $2.8M Grant by JDRF to Study Metformin and Type 1 Diabetes

BOSTON, Nov. 1, 2013 /PRNewswire/ -- T1D Exchange, the first program of the new nonprofit organization Unitio, has received a $2.8 million research grant from JDRF to study the use of metformin—a drug used as first-line treatment for type 2 diabetes—in combination with standard insulin therapy in overweight adolescents with type 1 diabetes.

The study will include a minimum of 136 adolescents with type 1 diabetes who are overweight and have failed to achieve optimal blood sugar control with insulin alone. Study participants will continue insulin therapy and will be randomly assigned to receive either metformin or a placebo. Blood sugar control and side effects of the treatment will be assessed over a 6-month period.  In a concurrent study involving a subset of the participants, testing will be done to assess whether metformin improves insulin sensitivity.

"We are very excited to partner with JDRF in this important study to better understand the benefits and risks of the use of metformin in overweight adolescents with type 1 diabetes and evidence of insulin resistance," said Dana Ball, executive director and co-founder of T1D Exchange. "JDRF and T1D Exchange share the goal of improving the lives of people with type 1 diabetes, and we look forward to future collaborative opportunities."

The efficacy of metformin, a drug that is used to control the amount of glucose in the blood of those with type 2 diabetes, is largely unknown for those with type 1 diabetes.

"For more than 90 years, insulin has been the primary therapy for people with type 1 diabetes; but the fact remains that despite vigilant management, glycemic control is a huge challenge for many with the disease," said Sanjoy Dutta, Ph.D., senior director of treat therapies at JDRF. "Previous studies have built a body of evidence showing the potential of certain adjunct therapies, such as metformin, to reduce insulin dependence, improve glucose control, and provide additional benefits to individuals with type 1 diabetes. Since metformin has been safely and effectively used for more than 50 years, positive results from this study could help to accelerate an improvement in the standard of care for people with type 1 diabetes—an important goal for JDRF."

Since its founding, T1D Exchange has been focused on understanding the root cause of type 1 diabetes in addition to realizing effective treatments, accelerating research, and helping to improve patient outcomes. Other T1D Exchange areas of focus include non-insulin therapies, factors contributing to severe hypoglycemia, and automated insulin delivery technologies.

About T1D Exchange
T1D Exchange was founded on the premise that finding faster, better therapies for type 1 diabetes (T1D) requires a research model as multi-faceted as the disease itself. T1D Exchange acts as a convener of the thousands of people working to improve patient outcomes already—by connecting them to one another and to the patient community at large. Drawing on decades of research and data that have come before, T1D Exchange aims to be the translational engine that enables the entire T1D ecosystem to collaborate in truly novel ways via the integration of a clinic network, clinic registry, biorepository, and the online patient/caregiver community, Glu.

For more information, please visit

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.

For more information, please visit

About Unitio
Unitio is a nonprofit organization whose mission is to connect researchers, physicians, and patients battling disease in a way that facilitates discoveries, accelerates treatments, and provides answers to some of the most pressing questions. Unitio's real-world, patient data platform is designed to accelerate all aspects of drug and device development via an integrated system of people and institutions already working hard to decode different parts of complex diseases by connecting them to one another and to their patient communities.

For more information, please visit

SOURCE T1D Exchange
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
2. U.S. Physician Prescribing Behavior Impacted by Health Insurance Exchanges and Accountable Care Organizations
3. InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
4. Assured Pharmacy, Inc. Announces 16% Senior Convertible Debenture and Warrant Exchange Offer
5. Singh & Associates and Sughrue Mion PLLC in association with Lex WITNESS present The IPR Exchange - An Indo US IPR Summit
6. Alere Inc. Extends Exchange Offer for 6.500% Senior Subordinated Notes due 2020
7. Experian Healthcare launches tool to enable providers to identify and help enroll eligible individuals for health insurance exchange (HIX) subsidized programs
8. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
9. New Research Finds Many Seniors Wrongly Think Public Health Insurance Exchanges Are Replacing Medicare Plans
10. Southeast Michigan Beacon Community to Integrate Laboratory Tests from Quest Diagnostics Into BeaconLink2Health Health Information Exchange
11. CVS Caremark Announces Agreement in Principle with the Securities and Exchange Commission
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):